CYP46A1 and glioblastoma: Probably, yes, as suggested by CYP46A1-containing adenoviral injections in the brain or EFV treatments of mouse models of different brain disorders, both neurodegenerative (e.g., Alzheimer’s, Huntington’s, and prion diseases, Niemann-Pick disease type C1, and spinocerebellar ataxia) and non-neurodegenerative (e.g., glioblastoma and depression) (Hudry et al., 2010; Burlot et al., 2015; Boussicault et al., 2016; Mast et al., 2017; Patel et al., 2017; Han et al., 2019; Kacher et al., 2019; Mitroi et al., 2019; Nobrega et al., 2019; Petrov et al., 2019a; Ali et al., 2021).